# DISC-3405

Source: https://onco.cc/drugs/disc-3405/  
OnCo record `disc-3405` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

DISC-3405 is an experimental monoclonal antibody from Disc Medicine, in phase 2 trials for polycythaemia vera.

## Summary

DISC-3405 (MWTX-003) is a monoclonal antibody from Disc Medicine, with Mabwell as licensor (formerly MWTX-003). An antibody against TMPRSS6 that induces hepcidin and so restricts iron for red-cell production, tested to control red-cell overproduction in polycythaemia vera. Its furthest stage is phase 2, for polycythaemia vera. ClinicalTrials.gov registers it in one study linked below. Phase 2 in PV (NCT06985147) active, not recruiting. Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-11-03
- Also known as: MWTX-003
- Tags: pipeline; ctgov-ingest
- Code: DISC-3405
- Modality: Monoclonal antibody
- Mechanism: An antibody against TMPRSS6 that induces hepcidin and so restricts iron for red-cell production, tested to control red-cell overproduction in polycythaemia vera.

## Sources

- Disc Medicine: discmedicine.com: https://www.discmedicine.com/pipeline
- Disc Medicine: discmedicine.com: https://www.discmedicine.com/pipeline
- ClinicalTrials.gov: trials of DISC-3405: https://clinicaltrials.gov/search?intr=DISC-3405

## Connected records

- cancers: [Myeloproliferative neoplasms (PV, ET, myelofibrosis)](https://onco.cc/cancers/myeloproliferative-neoplasms/)
- companies: [Disc Medicine](https://onco.cc/companies/disc-medicine/)
- trials: [A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)](https://onco.cc/trials/nct06985147/)

---
JSON: https://onco.cc/api/v1/entities/disc-3405.json